Shilpa Medicare's joint venture with Zydus, Oncosol, has received USFDA approval for IMKELDI, the first oral liquid formulation of imatinib for certain cancers. This innovative delivery system aims to improve patient adherence and dosing precision, particularly for those who struggle with swallowing. The company reported a significant rise in net profit and revenue for the September quarter, marking eight consecutive quarters of EBITDA improvement.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
